Replies to post #263557 on Bioelectronics Corp (BIEL)

[bielupandaway]

Amazing
These are 1st time orders. The only way we can continue these numbers if we continuously partner up with more and more OEM partners thereby giving is free advertising and marketing. We need recurring sales and this will only happen once the world starts speaking about it and the competition starts to pick up. No stopping till we have our devices globally and we hit every company on planet earth. There is no limit where this can reach if and when momentum starts picking up. Go Biel !!

[4toSchool]

>>>First quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company's strong growth, but also serve as objective evidence of effectiveness for the Company's strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.<<<

From yesterday's PR: $605,675 first quarter sales. Plus $306.000 to be recorded. Pretty good report IMO. Could million dollar sales become a quarterly norm soon? That should help the stock price. Like that we are seeing increasing sales quarter over quarter!

Did the $605,675 first quarter sales included the $554,000 deferred from 4th quarter 2020? If so, then could one restate 1st quarter sales, excluding deferral adjustments, as:

$605,675 - $554,000 + $306,000 = $357,675

OWN SNAP
Bioelectronics (BIEL) Moves Up On High Volume: Now What?
February 1, 2021 By Michael Rowels

If you are looking to get into stocks that have been displaying considerable momentum then it might be a good idea to track the Bioelectronics Corp (OTC: BIEL) stock.

The stock has displayed strong momentum in recent days and over the course of the last week, it managed to deliver gains of as much as 50%. The trigger for the rally in BioElectronics might have been the announcement of the company’s fourth-quarter results back on January 19.

BioElectronics managed to generate revenues of $519,000 in the quarter, which represents a massive jump of as high as 241% from the previous quarter.

The revenues stood at $152,000 in the third quarter. However, more importantly, the company announced that on top of the revenues it generated, there are going to be deferred revenues to the tune of $554,000. Lastly, the two biggest lenders to BioElectronics have also decided to forego interest payments totaling as much as $750,000 in 2020 and are going to do the same in 2021.

Michael Rowels

Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.

[pennytiger]

IMO it would have to be $2m or more per Qt., BIEL has done these numbers before, but the share structure was a lot lower, can't just take into account the increased sales, also have to look at the increased shares, which ends up diluting the share price!